Lung Cancer: "Lung-MAP" S1400 ~ Biomarker-Targeted Second-Line Therapy in Treating
Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
Will cancer cells respond better to standard treatment or one of the investigational
treatments when treatment is chosen based on genes and proteins within the cancer
cells called "biomarkers'?
Basic Study Information
Purpose:Location: cancer center
The purpose of this study screening step is to perform genetic tests on your tumor
sample for certain features that investigational targeted agents used in this study
are specifically designed to work against.
The purpose of the treatment part of this study is to compare the effects, good and
bad, of these investigational agents to the usual approach to treating your type of
cancer. It may be possible that you will not be able to participate in the treatment
part of this study. This could happen if it is unsafe for you to receive the investigational
treatment. You may also choose to not participate in the treatment portion of the
study. Before you decide to get treatment on the study, you will be given information
about the study treatment and you will be asked if you wish to continue on this research
The study has two steps:
• The initial screening step where we will examine your tumor tissue, and
• The sub-study treatment step which will be discussed in a separate consent form.
There will be many sub-studies that are open for patients at a given time. The sub-study
that you will be offered will depend on a combination of the results of the testing
done on your tumor sample, and which sub-studies are available when you are ready
to get treatment on this study. The testing done on you tumor sample is examining
the presence or absence of certain biomarkers. These biomarkers are either changes
in genes or proteins in cancer cells that may be associated with cancer growth.
If your tumor has just one biomarker with a sub-study designed for that biomarker,
you will be assigned to that sub-study. If your tumor has multiple biomarkers with
sub-studies designed for them, you will be assigned to one of the related biomarker
sub-studies randomly (by chance).
Additionally, once you are assigned to a sub-study, a computer will assign you by
chance to one of the treatment groups in the sub-study. This is called “randomization.”
This is done by chance because no one knows if one treatment is better or worse than
the other. In each of the sub-studies an investigational treatment will be compared
to a standard treatment.
Study Web URL: http://clinicaltrials.gov/ct2/show/NCT02154490?term=Phase+II%2FIII+Biomarker-Driven+Master+Protocol+for+Second+Line+Therapy+of+Squamous+Cell+Lung+Cancer&rank=1
Study Reference #: CLUN-14066
Lead Researcher (Principal Investigator)
Lead Researcher: Eric Kim
Study Contact InformationStudy Coordinator: Amy Jasek
Phone: (585) 273-1912
Additional Study Details
Learn More About These Conditions
More information about Carcinoma, Squamous Cell
More information about Lung Cancer
Trial Not Found
The study you are looking for is not active at this time.
Return to Search